Digital Commons @ University of Georgia
School of Law
Scholarly Works

Faculty Scholarship

4-1-2012

Gene Patents No More? Deciphering the Meaning of Prometheus
Fazal Khan
University of Georgia School of Law, fkhan@uga.edu

Lindsay Kessler

Repository Citation
Fazal Khan and Lindsay Kessler, Gene Patents No More? Deciphering the Meaning of Prometheus , 2
Annals Health L. Informed Consent 19 (2012),
Available at: https://digitalcommons.law.uga.edu/fac_artchop/920

This Article is brought to you for free and open access by the Faculty Scholarship at Digital Commons @ University
of Georgia School of Law. It has been accepted for inclusion in Scholarly Works by an authorized administrator of
Digital Commons @ University of Georgia School of Law. Please share how you have benefited from this access
For more information, please contact tstriepe@uga.edu.

B E AZ L E Y I N S T I T U T E F O R
H E AL T H L AW AN D P O L I C Y

Annals
OF

Health

Law

INFORMED CONSENT
Volume 2 | Issue 2

SPRING 2012

ANNALS OF HEALTH LAW
THE HEALTH POLICY AND LAW REVIEW OF
LOYOLA UNIVERSITY CHICAGO SCHOOL OF LAW
BEAZLEY INSTITUTE FOR HEALTH LAW AND POLICY
EDITOR-IN-CHIEF
Daniel Marino
PUBLICATIONS EDITOR
Alexandria Ottens

TECHNICAL PRODUCTION EDITOR
Doriann Cain

MARKETING & COORDINATING EDITOR
Laura Ashpole

SYMPOSIUM EDITOR
April Schweitzer

ADVANCE DIRECTIVE EDITOR
Seth Knocke
ANNALS SENIOR EDITORS
Matt Ennis
Lyndsay Gunkel

Krystina Mendoza

ADVANCE DIRECTIVE SENIOR EDITOR
Gretchen Thomas
ASLME SPECIAL EDITION EDITOR
Chris Carlson

Sam Richardson
William VanMeter
EDITOR-AT-LARGE
Cameron Webb

INFORMED CONSENT SENIOR EDITOR
Stephen Samlan

MEMBERS
Andrew Holmstrom
Karim Hussein
Matthew Jones
Erin Lau
Ashley Leonard
Jennifer Lorio
Timothy Loveland
Emily Lowe
Christopher McAdam
Margaret Mendenhall
Peter Nozicka
Logan Parker

Nikhil Bafna
Michaela Bantilan
Timothy Black
Alissa Bugh
Keshia Carswell
Ashley Craig
Britany Fijolek
Kelly Gallo
Carrie Gilbert
Patrick Gleeson
Karla Guerrero
Alexandra Hall

Kristin Peterson
Elisa Pleasant
Mira Radadia
Ghadir Rezko
Jason Robin
Jeremy Ross
Daniel Shore
Briar Siljander
Jenna Steffy
Brian Troutman
Sean Walter
Jolianne Walters

FACULTY ADVISORS
Lawrence E. Singer, J.D., M.H.S.A.
Director and Professor of Law, Beazley Institute for Health Law and Policy
Loyola University Chicago School of Law
John D. Blum, J.D., M.H.S.
John J. Waldron Research Professor of Health Law
Loyola University Chicago School of Law
BUSINESS MANAGER
Carla Weil
VOLUME 2, ISSUE 2

SPRING 2012

ANNALS OF HEALTH LAW
INFORMED CONSENT
PURPOSE
The Annals of Health Law strives to publish articles for a broad readership which make a
contribution to the teaching, practice, and/or public policy surrounding health law. In furtherance of that
goal, the Annals critically reviews its publication medium, style, and content to ensure that it continues to
distribute high quality, relevant content. Informed Consent is a product of this goal.
With the proliferation of digital media, Informed Consent responds to the need for a more immediate
release of practical articles related to the fields of health law and policy. Given this new focus, Informed
Consent is designed to assist healthcare attorneys, executives, consultants, and students in daily research
and practice.
With respect to the form and frequency of the publication, Informed Consent will periodically
publish articles that are less formal than might be expected in other law student edited publications.
Articles will be selected based on their ability to provide the readership with practical guidance that can
be applied to comprehending novel issues, developing legal strategies, and advising clients. Law students
are particularly well-positioned to accomplish these goals. Accordingly, articles may consist of studentwritten pieces developed as part of their coursework. Pieces may also be authored by professionals
looking for an outlet to discuss new developments in healthcare.
Given the novelty of much of the subject matter and the expertise of the authors on a given
subject, Informed Consent may not contain extensive supporting authority that would be expected in a
formal law review publication. Although we will not require authority for content reflecting the author’s
expertise on a matter, Informed Consent articles will still go through a rigorous substantive and technical
review process to maintain the Annals of Health Law’s academic integrity. Authors should generally
allow for a six to ten week editing timeline beginning after an article is selected for publication.

ANNALS OF HEALTH LAW
INFORMED CONSENT
INFORMATION FOR CONTRIBUTORS
About the Annals of Health Law Publications: The Beazley Institute for Health Law and Policy publishes the
Annals, a bi-annual journal, which contains original articles of particular relevance to health care practitioners,
policy makers, and scholars. The Annals has been published since 1992 and is managed and edited entirely by
students.
The Annals also publishes articles authored by its members in Advance Directive, an online component of the
Annals that presents a wide range of perspectives on emerging issues in health law.
Informed Consent is the newest publication by the Annals. Informed Consent is a periodic paper series aimed to
promote immediate release of articles relevant to the research in and practice of health law.
We invite you to view Advance Directive and Informed Consent at www.luc.edu/annals.
Request for Submissions: We would like to request submissions from any attorneys, consultants, other
professionals in the healthcare industry, and students who believe they have an interesting and practical piece to
share via Informed Consent.
Topic Guidelines: Articles submitted must meet certain guidelines prior to being considered for publication. As
seen below, these guidelines do not attempt to constrain the creative strengths of potential authors, but should be
used as an effort to maintain uniformity for publication style. We will accept topics on a variety of issues, but
articles should be geared towards issues facing those practicing or working in the healthcare industry. Examples:
o
o
o
o
o

Executing Bundled Payments
Complying with HITECH Act requirements
Establishing Accountable Care Organizations
Reimbursement Enhancement Strategies
Completing a CON Application

Format: Articles should be approximately 10-15 pages in length. We will occasionally accept articles outside this
range, but we advise that authors contact us prior to submission if the article length varies considerably from these
standards. Articles should conform to The Bluebook: A Uniform System of Citation (19th ed. 2010), published by the
Harvard Law Review Association. (All citations should be contained in footnotes.) The article should be in a
Microsoft Word file. Please include your name, title, and degrees at the top of the first page and your current resume
or curriculum vitae. We also request an abstract of 250 words or less.
Submission Address: Completed articles should be submitted via email at annalshl@luc.edu. Alternatively, articles
may be submitted to Editor-in-Chief, Annals of Health Law, Beazley Institute for Health Law and Policy, Loyola
University Chicago, School of Law, 25 East Pearson Street, Chicago, IL 60611.
Copyright: A statement transferring copyright to Loyola will be required for articles that are accepted for
publication. We will supply the necessary forms for transfer.
Reprints: Copyright © 2012 by Loyola University Chicago School of Law, Beazley Institute for Health Law and
Policy. Please send your reprint requests to Business Manager via email at annalshl@luc.edu or via fax at
312.915.6212.
Disclaimer: The ideas expressed herein are those of the authors and do not necessarily represent the views of the
Beazley Institute for Health Law and Policy, the staff of the Annals of Health Law, or Loyola University Chicago
School of Law

Gene Patents No More? Deciphering the Meaning
of Prometheus
Dr. Fazal Khan* and Lindsay Kessler**ǂ
I. INTRODUCTION
When Congress enacted the United States Patent Act in 1952, it specified
that patentable subject matter included anything “under the sun that is made
by man.” 1 Three decades ago the United States Patent and Trademark
Office (USPTO) issued the first gene patent and ushered in a brave new
gold rush. Some genes are associated with specific diseases, so being able
to identify these sequences is an essential first step for developing genomic
diagnostic tests and therapies. The problem with gene patents is that they
allow modern-day prospectors to cordon off access to naturally occurring
DNA sequences and exclude others from conducting research or developing
useful applications based on these sequences. In 2009, a broad coalition of
plaintiffs challenged Myriad Genetics over its breast cancer gene patents.
In July 2011, the U.S. Court of Appeals for the Federal Circuit ruled 2-1 in

* Dr. Fazal Khan teaches at University of Georgia School of specializing in health law. He
earned his bachelor’s degree from the University of Chicago and his medical (M.D.) and
legal (J.D.) degrees from the Medical Scholars Program at the University of Illinois at
Urbana-Champaign. His current research focuses on reform of the American healthcare
system, the effect of globalization on healthcare and the challenge of regulating emerging
biotechnologies. Representative articles and presentations include proposals on:
administrative regulations to protect against epigenetic harms (and endocrine disruptors) in
consumer products; ethical regulations on human drug trials in developing countries;
rethinking public health laws post-9/11 to ensure adequate protection of civil liberties and
effective emergency response; the potential dissonance between personal health records and
electronic medical records; and ethical safeguards that would allow organ donation from
anencephalic infants.
Dr. Khan and Ms. Kessler would like to thank Kirk Hartley of LSP Group, LLC in Chicago,
IL for his dedication, passion and inspiration for this article.
** Lindsay Kessler is an Associate Attorney [November 2012] in the Health Care Practice
Group of Polsinelli Shughart PC in Chicago, IL. J.D. 2012 with Health Law Certificate,
Loyola University Chicago School of Law, B.A. 2009, University of Illinois at UrbanaChampaign.
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Chicago, IL for his dedication, passion and inspiration for this article.
1. Jonah D. Jackson, Something Like the Sun: Why Even “Isolated and Purified” Genes
Are Still Products of Nature, 89 TEX. L. REV. 1453, 1454 (May 2011).
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favor of upholding Myriad’s gene patents, overturning a lower court
decision.
On March 20, 2012, Mayo Collaborative Services v. Prometheus
Laboratories, Inc. 2 (Prometheus) potentially restored sanity on the issue of
whether gene sequences can be patented. While not addressing gene patents
specifically, a unanimous Supreme Court correctly reaffirmed that one
cannot patent “the underlying laws of nature themselves.” 3 However, the
Court explicitly linked its decision to the viability of gene patents when less
than a week later it vacated the Myriad decision and remanded it back to the
Federal Circuit to reconsider in light of its ruling in Prometheus.
While it is not definitively clear that gene patents are dead in light of
Prometheus, this essay argues that properly understanding the Supreme
Court’s logic should lead to no other result. 4 Predicting whether the
“patent-friendly” Federal Circuit reaches the same conclusion is not the
focus of this essay. 5 Instead, this essay serves to rebut claims that gene
patents are consonant with patent law and needed to stimulate genomics
research and development.
Through the lens of the Myriad case, we will recount why there was such
a strong public interest movement against recognizing such patents.
Specifically, we will show how this particular patent stifles research,
impedes access to affordable testing, and detrimentally effects future
developments in the cancer world. Furthermore, we will briefly examine
the Supreme Court’s legal reasoning in Prometheus and why it should be
read as invalidating gene patents.
II. CHALLENGING MYRIAD
The ACLU and 20 others initiated the lawsuit against Myriad Genetics
on May 12, 2009, officially challenging the BRCA1/2 gene patent. The
joined parties comprised of researchers, genetic counselors, women
patients, cancer survivors, breast cancer and women’s health groups,
scientific associations representing 150,000 geneticists, pathologists and
laboratory professionals. Generally, the Plaintiffs pursued attacks on 4

2.
Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289
(2012).
3. Prometheus, 132 S. Ct. at 1305.
4. Andrew Pollack, Justices Send Back Gene Case, N.Y. TIMES, Mar. 26, 2012, at B1,
available at http://www.nytimes.com/2012/03/27/business/high-court-orders-new-look-atgene-patents.html.
5. Myriad’s stock fell the day of the Prometheus decision, as investors feared it meant
that the Supreme Court was inclined also to rule that genes could not be patented. However,
Myriad’s stock rose 56 cents to $23.34 on Monday, perhaps because the Supreme Court will
now not be hearing the case itself, instead leaving it to the presumably more patent-friendly
appellate court. See id.
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patent categories: (1) patents on natural human genes, (2) patents on genes
with natural mutations, (3) patents on any method of looking for mutations
in natural human genes, and (4) patents over the general thought that genes
are different with different effects, which correlate with an increased risk of
beast and/or ovarian cancer. 6 Before issuing a final opinion, the presiding
judge denied the Defendants’ motion to dismiss in November of 2009,
which some understood as Judge Sweet recognizing the case’s importance
for medical research and innovation. 7 Later, on March 29, 2010, the district
court granted the Plaintiffs’ motion for summary judgment, effectively
declaring Myriad’s patents invalid based on the theory that they contain
products of nature and abstract ideas. 8 Shortly after, the Defendants
announced its plans to appeal the decision. 9
On July 29, 2011, the appellate court found for Myriad Genetics,
reversing in part the prior decision.10 In the majority opinion, the court first
held that isolated DNA does not stem from products of nature, and therefore
is patent-eligible. 11 Similarly, the “growing and determining method”
Myriad utilizes for screening potential cancer therapeutics was held valid.12
However, the “comparing” or “analyzing” diagnostic method used on DNA
sequences held not patent-eligible, because they involve abstract mental
processes. 13 Yet the court’s decision regarding the products of nature
doctrine was a close one at 2-1, with a strong dissenting opinion. 14 The
ACLU and Myriad Genetics each filed petitions for rehearings in August
2011, but both were denied. 15 Following this decision, the ACLU filed a
writ of certiorari to the US Supreme Court,16 on December 6, 2011. 17
6. Marissa Noelle Pins, Impeding Access to Quality Patient Care and Patient Rights:
How Myriad Genetics’ Gene Patents are Unknowingly Killing Cancer Patients and How to
Calm the Ripple Effect, 17 J. INTELL. PROP. L. 377, 379 (Spring 2010).
7.
See Association for Molecular Pathology v. United States Patent and Trademark
Office, 669 F. Supp. 2d 365 (S.D.N.Y. Nov. 1, 2009) [hereinafter Order to Deny
Defendants’ Motion to Dismiss].
8. Association for Molecular Pathology v. United States Patent and Trademark Office,
702 F. Supp. 2d 181 (S.D.N.Y. 2010).
9. Pins, supra note 6, at 382.
10. Association for Molecular Pathology v. United States Patent and Trademark Office,
653 F.3d 1329, 1333 (Fed. Cir. 2011).
11. Id. at 1350.
12. See id. at 1357.
13. Id.
14.
John Conley, ACLU and Myriad Both Seek Further Federal Circuit Review,
GENOMICS LAW REPORT (Sep. 2, 2011), http://www.genomicslawreport.com/index.php/
2011/09/02/aclu-and-myriad-both-seek-further-federal-circuit-review/.
15. Id.
16.
Allison Dobson, Classen: Has the Federal Circuit Lost Interest in Patentable
LAW
REPORT
(Sep.
14,
2011),
Subject
Matter?,
GENOMICS
http://www.genomicslawreport.com/index.php/2011/09/14/classen-has-the-federal-circuitlost-interest-in-patentable-subject-matter/.
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Additionally, the USPTO scheduled two hearings “on independent second
opinion genetic testing where patents and exclusive licenses exist that cover
primarily genetic diagnostic tests,” for February 16 and March 9, 2012. 18
As we now know, these hearings are moot following Prometheus.
III. LEGAL ARGUMENTS
To be eligible for a patent in the United States, the USPTO must certify
that the invention meets three separate conditions: (1) it must be novel, (2)
it must have utility, and (3) it must be nonobvious. 19 When it comes to
biological material, whether genetic or not, much controversy surrounds the
patent-eligibility of those “inventions” naturally occurring in humans.
When the Patent Act was enacted in 1952, it included any subject matter
“under the sun that is made by man.” 20 Later, this assertion was modified
when patents were prohibited on the laws of nature, physical phenomena,
and abstract ideas and mental processes, otherwise known as the product of
nature doctrine. 21 These three exceptions to patent-eligibility come from a
1980 United States Supreme Court case, Diamond v. Chakrabarty, which is
the first and only decision directly addressing the patentability of living
organisms. 22 The Court in Chakrabarty upheld a patent for a laboratorycreated bacterium with properties not found in nature, and two years later
the USPTO granted its first human genetic material patent.23
The patent system was originally designed to grant certain rights to
inventors for their inventions in order to reward and encourage human
ingenuity. 24 But like the ACLU argues, genes are not inventions but rather
are natural parts of the human body. In fact, the USPTO recognizes this
differentiation by maintaining the Chakrabarty exception, that products of
nature not patentable. 25 However, a genetic sequence may qualify if it is

17. Kevin Noonan, Plaintiffs File Petition for Certiorari in AMP v. USPTO, PATENT
DOCS (Dec. 8, 2011), http://www.patentdocs.org/2011/12/plaintiffs-file-petition-forcertiorari-in-amp-vuspto.html?utm_source=feedburner&utm_medium=email&utm_
campaign=Feed%3A+PatentDocs+%28Patent+Docs%29.
18.
Donald Zuhn, USPTO to Hold Hearing on Genetic Diagnostic Testing, PATENT
DOCS (Feb. 15, 2012), http://www.patentdocs.org/2012/02/uspto-to-hold-hearing-on-geneticdiagnostic-testing.html?utm_source=feedburner&utm_medium=email&utm_campaign
=Feed%3A+PatentDocs+%28Patent+Docs%29.
19. Pins, supra note 6, at 385.
20. Jackson, supra note 1, at 1454.
21. Id.
22. Id.
23. Id.
24. AMERICAN CIVIL LIBERTIES UNION, Frequently Asked Questions: Legal Challenge to
Patenting of Human Genes (Sep. 10, 2010), available at http://www.aclu.org/
files/assets/legal_faq_brca.pdf [hereinafter ACLU FAQ].
25. Id.
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“isolated and purified,” through removing the gene from the human body
and stripping away the “non-coding regions.” 26 Yet the ACLU challenges
the isolation and purification process as applied to human genes, and argues
that the process is “simple enough for any graduate student in genetics or a
related field to perform.” 27 Therefore, the ACLU analogizes the BRCA1/2
process to removing gold from a mountain and then patenting the gold,
therefore violating the ingenuity and non-obvious requirements for
patentable material.28
IV. WHY PROMETHEUS SHOULD BE READ AS INVALIDATING GENE
PATENTS
Only months after the Supreme Court granted certiorari to Myriad, the
Court ruled a blood test patent developed by Prometheus invalid,
reinforcing the “law of nature” doctrine.29 The test at issue looked at the
chemical reaction after prescribing a drug, enabling a doctor to modify the
dosage and make the treatment more effective or avoid unwanted side
effects. 30 In a unanimous decision, Justice Breyer wrote that inventors must
do more than “recite a law of nature and then add the instruction “apply the
law.” 31 As discussed below, the concerns raised by the Court in Prometheus
are directly applicable to Myriad’s gene patents.
Myriad Genetics’ strict enforcement of its license created a monopoly in
the field of BRCA 1/2 testing. Using its patent power, Myriad has sent
several cease-and-desist letters to laboratories and researchers throughout
the United States, telling them to stop testing. 32 Out of fear of patent
infringement penalties, this has resulted in a chilling effect among the
various parties who deal with diagnostic testing. Dr. Harry Ostrer, a
professor of pediatrics, pathology, and medicine, and a plaintiff in the
case, 33 is a working example of this fear that many are experiencing. Dr.
Ostrer was unable to provide patients with results of BRCA1/2 tests due to
Myriad’s patent, something he desired to do, and testified he would do if

26. Id.
27. Id.
28. Id.
29. Pollack, supra note 4.
30. Id.
31. Id.
32. AMERICAN CIVIL LIBERTIES UNION, Legal Challenge to Human Gene Patents, 2, 6
(June 27, 2009), http://www.aclu.org/files/pdfs/freespeech/brca_qanda.pdf [hereinafter Legal
Challenge to Human Gene Patents].
33.
Plaintiff statement from Harry Ostrer, M.D., AMERICAN CIVIL LIBERTIES UNION,
BRCA-Plaintiff Statements, (May 12, 2009), http://www.aclu.org/free-speech_womensrights/brca-plaintiff-statements#ostrer [hereinafter Ostrer].
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the patent was invalidated. 34 Dr. Ostrer displayed frustration with the
BRCA1/2 patent as it currently stands:
Currently, I am recruiting hundreds of women into a new study to
identify other genes associated with a risk of breast
cancer. . .Unfortunately, once such new genes are identified, the use of
this information in clinical practice could be limited because it might be
viewed by Myriad Genetics as infringing on its BRCA patentsFalse
Every day I think about how the findings of the research laboratory can
35
be translated into new genetic tests that might benefit, not harm, people.

In 2010, Myriad Genetics brought in $353 million (88 percent of their
total revenue) from the breast cancer test.36 However, the industry has not
seen any new innovation from Myriad in the past five years, when it last
introduced the most recent BRCA1/2 test. 37 Executives at Myriad say they
plan to prepare for technological improvements, in response to claims of
newer DNA-sequencing techniques being faster and less expensive
compared to the technology that Myriad uses, reportedly from the 1990s.38
Admittedly, former Myriad employee Sean Tavtigian said that the company
“is trying to catch up, but it’s going kind of slow.” 39
In fact, Life Technologies has developed a new Proton Sequencer that
can read an entire person’s genome for $1,000 40 - less than Myriad charges
for just two genes. A British company, Oxford Nanopore, has followed suit
and recently introduced the world’s first miniature DNA sequencer and will
be available commercially this year for $900.41 But because of strict patent
protection on BRCA1/2, lawyers remain unsure whether other methods, like
full gene sequencing, would violate Myriad’s patents on the isolated
genes. 42 Some predict that when Myriad’s patents expire, the price of
whole genome sequencing will trend as low as $100, and single-gene test
34. Id.
35. Declaration of Harry Ostrer, M.D., available at http://docs.justia.com/cases/federal/
district-courts/new-york/nysdce/1:2009cv04515/345544/47/0.pdf?ts=1251485192.
36. Andrew Pollack, Despite Gene Patent Victory, Myriad Genetics Faces Challenges,
N.Y. TIMES, Aug. 24, 2011, at B1, available at http://www.nytimes.com/2011/08/25/
business/despite-gene-patent-victory-myriad-genetics-faces-challenges.html?pagewanted=all
[hereinafter Myriad Genetics Faces Challenges].
37. Ostrer, supra note 35.
38. Myriad Genetics Faces Challenges, supra note 38.
39. Id.
40.
Clive Cookson, Machine to read individual’s DNA for $1,000, FINANCIAL TIMES
(Jan.
10,
2012),
http://www.ft.com/intl/cms/s/2/e3c6b7bc-3ac3-11e1-a75600144feabdc0.html%23axzz1maUoc31U
41. Clive Cookson, Oxford Nanopore unveils mini-DNA reader, FINANCIAL TIMES (Feb.
17,
2012),
http://www.ft.com/intl/cms/s/2/318a378a-5900-11e1-b118-00144feab
dc0.html#axzz1oixikxkx [hereinafter Oxford Nanopore].
42. Myriad Genetics Faces Challenges, supra note 38.
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methods will be moot. 43
In other words, the exact concerns raised by the Supreme Court in
Prometheus directly support the ACLU in its fight against Myriad. The
Court argued that Prometheus’ blood test patent directs a treating physician
towards a particular course of action, imposing on the sanctity of the
doctor-patient relationship. Explicitly the Court recognizes that these
patents “tie up the doctor’s subsequent treatment” and “threaten to inhibit
the development of more refined treatment recommendations.” 44 Further,
Prometheus’ patent encourages physicians to discard crucial treatment
factors such as individual patient characteristics and physician’s own
medical inferences in favor of a metabolic blood test. 45 In the world of
patent eligibility, Prometheus forces applicants and courts to reconsider the
law of nature prohibition, as opposed to the equally controversial novelty,
and non-obviousness requirements.
V. CONCLUSION
Before Prometheus, gene patent opponents faced an uphill battle. With
almost thirty years of patent law affirming the patentability of genes 46 and a
struggling economy, companies like Myriad Genetics have found a source
of revenue they will fight to protect. While some earlier predicted that the
USPTO is not ready to change its standards, 47 Prometheus has changed the
analytical framework regarding human gene patents.
Myriad Genetics cautioned about the negative repercussions that would
result in finding for the Plaintiffs, claiming that the entire foundation of the
biotechnology industry would unravel if human gene patents were
invalidated. 48 This facile argument overlooks the advantages that could
result if other companies are allowed to compete. Most importantly, the
cancer patients who need access to the BRCA1/2 test would have more
affordable insurance options because more laboratories would offer the test.
For individuals like Vicky Thomason who are unable to pay for BRCA1/2,
and “get up every day not knowing if [they] have a mutation,” 49 this can
make an incredible difference. The possibilities are endless if Myriad’s
43. THE ECONOMIST, More harm than good? Patenting genes is bad for diagnosis, Apr.
15, 2010, available at http://www.economist.com/node/15905837?story_id=15905837.
44. Prometheus, 132 S. Ct. at 1302.
45. Id.
46. Jackson, supra note 1, at 1487.
47. Id.
48. Miri Yoon, Gene Patenting Debate: The Meaning of Myriad, 9 J. MARSHALL REV.
INTELL. PROP. L. 953, 973-74 (Spring 2010).
49.
Plaintiff statement from Vicky Thomason. AMERICAN CIVIL LIBERTIES UNION,
BRCA-Plaintiff Statements, (May, 12,2009) http://www.aclu.org/free-speech_womensrights/brca-plaintiff-statements#thomason.
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gene exclusivity ends: researchers would gain access to valuable data, more
efficient testing methods could be developed, and future developments on
the BRCA1/2 gene would not be seen as patent infringement. For the first
time in patent history, the ACLU is questioning a human gene patent on
constitutional grounds. 50
Arguably, the Supreme Court granted certiorari in Myriad for the limited
purpose of vacating and remanding the case for consideration in light of
Prometheus. 51 Prometheus directly contradicts the appellate court’s
decision to uphold Myriad’s patents. With the case on remand, hopefully
the court will follow Prometheus’ lead and set new precedent for human
gene patent litigation in the future. Once the natural phenomena component
of Myriad’s claims are stripped away, the court will consider the Myriad’s
contribution to the BRCA1/2 test.52 “It then comes down to whether
Myriad added anything non-routine or non-conventional, beyond that law
of nature, to make it patentable.” 53 More crucial to the Court is the concern
that scientists are unable to do research without infringing on the BRCA1/2
patent - not only does Myriad’s exclusivity stifle innovation and cancer
research, but also it intrudes on the practice of medicine as a profession. 54
After Prometheus, there is now real hope that gene patents will not impede
the progress of researchers and medical professionals seeking to help
patients through a better understanding and application of nature’s laws.

50.
Ann Weilbaecher, Can Patent Protections Trample Civil Liberties? The ACLU
Challenges the Patentability of Breast Cancer Genes, 15 PUB. INT. L. REP. 10, 17 (2009).
51. John Conley & Dan Vorhaus, Myriad Finally Reaches the Supreme Court (But Only
(Mar.
27,
2012),
http://
For
a
Moment),
GENOMICS LAW REPORT
www.genomicslawreport.com/index.php/2012/03/27/myriad-finally-reaches-the-supremecourt-but-only-for-a-moment/.
52. See Christine Livoti, Myriad’s gene patents case may still end up at Supreme Court,
FINANCIAL TIMES (Apr. 3, 2012), http://www.ft.com/intl/cms/s/2/ebad0c7a-7dca-11e1-9adc00144feab49a.html#axzz1rg2V5HoW.
53. Id.
54. See id.

